CD5 deletion enhances the antitumor activity of adoptive T cell therapies
Ruchi P. Patel(University of Pennsylvania), Patrizia Porazzi(Hospital of the University of Pennsylvania), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Linhui Chen(Hospital of the University of Pennsylvania), Stefan K. Barta(University of Pennsylvania), Alberto Carturan(Hospital of the University of Pennsylvania), Mathew G. Angelos(University of Pennsylvania), David T. Teachey(Children's Hospital of Philadelphia), Seok Jae Hong(Parker Institute for Cancer Immunotherapy), Maria Wysocka(University of Pennsylvania), Arati A. Inamdar(University of Pennsylvania), Dean Qian(Oncoceutics (United States)), Hatcher J. Ballard(University of Pennsylvania), Jaryse Harris(Hospital of the University of Pennsylvania), Guido Ghilardi(Hospital of the University of Pennsylvania), Stefano Pileri(European Institute of Oncology), Luca Paruzzo(Hospital of the University of Pennsylvania), Nicholas A. Siciliano(Oncoceutics (United States)), Puneeth Guruprasad(Parker Institute for Cancer Immunotherapy), Tatiana Blanchard(University of Pennsylvania), Antonia Rotolo(University of Pennsylvania), Trang Vu(Oncoceutics (United States)), Olga Shestova(University of Pennsylvania), Daniel J. Powell(Democritus University of Thrace), Inkook Chun(Parker Institute for Cancer Immunotherapy), Adam E. Snook(Thomas Jefferson University), Alain H. Rook(University of Pennsylvania), C Sauter(Parker Institute for Cancer Immunotherapy), Mohamed Abdel‐Mohsen(The Wistar Institute), Gerald P. Linette(University of Pennsylvania), Stephen J. Schuster(Hospital of the University of Pennsylvania), Aditya Nimmagadda(Oncoceutics (United States)), Avery D. Posey(Translational Therapeutics (United States)), Raymone Pajarillo(Hospital of the University of Pennsylvania), Carolyn E. Shaw(University of Pennsylvania), Khatuna Gabunia(University of Pennsylvania), Vinodh Pillai(Children's Hospital of Philadelphia), Yi‐Hao Chiang(Mackay Memorial Hospital), John Scholler(University of Pennsylvania), Michael Wang(St. Joseph Health System), Ki Hyun Kim(Hospital of the University of Pennsylvania), Aasha Gupta(University of Pennsylvania), David M. Barrett(Children's Hospital of Philadelphia), Wei Xie(Union Hospital), Yunlin Zhang(Hospital of the University of Pennsylvania), Steven Yang(Oncoceutics (United States)), Ivan Cohen(Hospital of the University of Pennsylvania), Beatriz M. Carreno(California University of Pennsylvania), Chong Xu(Parker Institute for Cancer Immunotherapy), Yong Gu Lee(Parker Institute for Cancer Immunotherapy)
Cited by 45
Related Papers
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
|The Journal of Experimental Medicine|2000|5.2k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829